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Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of neoplasms, according to the World 
Health Organisation International Classification of Diseases Version 2010. Results: 
The FDA approved a total of 55 cancer drugs between 2004 and 2013 compared to 
45 by the PMDA, of which 24 drugs were approved by both organisations. Although 
less than half of currently FDA-approved cancer drugs are approved by the PMDA, 
87.5% of drugs approved by the FDA between 2004 and 2007 have subsequently been 
approved by the PMDA with an average delay of 2.95 years. Of the total number of 
drugs for all indications, 21% of FDA-approved drugs and 16% of PMDA-approved 
drugs were indicated for oncology. Although the proportion of drugs focused on 
breast cancer, lymphoma and bone marrow disorders were similar between the 
two organisations; the FDA had a higher proportion of drugs indicated for leuke-
mias and prostate cancer, whilst the PMDA had a larger focus on colorectal cancer 
drugs. ConClusions: From the analysis presented here, there are clear differ-
ences between cancer drug approval in Japan and the USA with regards to time-to-
approval of new drugs, as well as the specific treatment areas for which new drugs 
have been submitted.
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objeCtives: To review prevalence and risk factors of trastuzumab’s cardiotoxic 
effects in breast cancer patients. Methods: Retrospective chart review of 20 cases 
recieved trastuzumab for breast cancer treatment at Phramongkutklao hospital dur-
ing 2010-2011. Results: Average age of patients in this study was 58.2 +/- 9.3 years 
old. The most common stage of breast cancer were stage III (11/20, 55%). Average 
cycle per patients was 21.3 +/- 10.1. There were 12 patients (60%) completed 1 year 
course of treatment, 7 patients still recieving the treatment and 1 patient had to 
discontinue treatment before completion. There were 13 patients (65%) had declin-
ing in percentage of left ventricular ejection fraction after trastuzumab treatment, 6 
(46%) patients had less than 10% declining of left ventricular ejection fraction, equal 
to number of patients with 11-20% declining of left ventricular ejection fraction (6 
out of 12, 50%). In this study, we found 1 patients who had to discontinue treatment 
due to over 20% declining of ejection fraction. Due to the small number of cases, 
we did not found any statistical significant for the risk factors associated with the 
declining in ejection fraction among patients recieved trastuzumab treatment in 
this study. ConClusions: Cardiotoxicy in term of declining in percentage of left 
ventricular ejection fraction was not uncommon among breast cancer treated with 
trastuzumab. Closely monitoring patients with schedule echocardiogram is war-
ranted for safety use of this drug.
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objeCtives: The Chinese oncology market is increasingly important to multina-
tional and local pharmaceutical companies. However, access to high-cost medicines 
is fragmented within China. This study explored current prescribing and reimburse-
ment of high-cost, targeted therapies and differences between Tier 1 and Tier 2/3 
cities. Methods: Some 76 oncologists from different tier cities were surveyed 
regarding their current and expected future prescribing for gastric cancer (GC) and 
hepatocellular carcinoma (HCC). In addition, payers who influence reimbursement 
at national and/or regional levels were interviewed. Results: Chemotherapy still 
dominates GC and HCC treatment in China, with limited use of high-cost targeted 
therapies; reimbursement is considered the greatest barrier to accessing targeted 
therapies. Almost 60% of HCC patients do not receive sorafenib due to cost/reim-
bursement-related reasons. Patient assistance programs and private insurance 
schemes, along with government initiatives such as negotiation for selective pro-
vincial formularies inclusion and “disastrous diseases” coverage will help break this 
barrier. Patient share of high-cost GC and HCC therapies is expected to double over 
the next three years. We also found disparity in access to cancer therapies between 
different tier cities. More patients in Tier 1 cities have urban resident basic medical 
insurance than in Tier 2/3 cities (34% versus 24%). In Tier 1 cities, relatively more 
patients receive targeted therapy (23% versus 16%), compared with Tier 2/3 cities. 
Another compounding factor is that the cost of these therapies is lower in Tier 1 cit-
ies than in most Tier 2/3 cities (trastuzumab costs $1800 per cycle in Shanghai versus 
$2500 in Shijiazhuang). ConClusions: There is huge opportunity for high-cost 
cancer therapies in China; however, uneven reimbursement between cities means 
local market access strategies are required to maximize patient share.
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objeCtives: Aim of the study was concerned with formulation and evaluation of 
mouth dissolving tablets. Fluconazole is a broad spectrum triazole derivative useful 
in treatment of oropharyngeal and esophageal candidiasis, but it is poorly water 
soluble drug, for that an attempt was made to form complex with β -Cyclodextrin 
to make it water soluble and then deliver via buccal mucosa. Methods: The tab-
lets were prepared by wet granulation method using permeation enhancer and 
solubilizing agent β -Cyclodextrin and other excipients using 32 factorial designs. 
The amount of drug in each tablet was 50 mg and average weight of each tablet 
was found to be 230 mg. The prepared tablets were evaluated and compared in 
vey was conducted in 87 cervical cancer patients admitted to Dr. Sardjito Hospital, 
a referral hospital in Yogyakarta Province-Indonesia, between June to December 
2013. Data on HRQOL was collected using EQ-5D-3L (Indonesian version). As no 
Indonesian-EQ-5D-3L value set exists, Malaysian value set was used to calculate 
utility among these patients. Results: About 14%, 51%, 31% and 5% of patients 
were in stage I to IV, respectively. The most frequently reported problems were pain/
discomfort (67.82%) and anxiety/depression (57.47%). The mean of EQ-5D VAS score 
was 75.83 (SD= 17.03). The mean utility value was 0.830 (SD= 0.182), 0.751 (SD= 0.188), 
0.704 (SD= 0.205), and 0.766 (SD= 0.131) for patients with stage I to IV, respectively. 
Based on the stage of cervical cancer, the proportion of patients reporting problems 
in each dimension tended to increase from stage I to stage IV while the EQ-5D VAS 
score tended to decrease from stage I to stage IV. The utility value also tended to 
decrease from stage I to stage III, however it rather increased for patients with stage 
IV. ConClusions: Cervical cancer significantly affects patient’s HRQOL. Effort 
should be made to improve the quality of life of cervical cancer patients especially 
in term of pain /discomfort and anxiety/depression reduction.
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objeCtives: Personalized medicine along with successful delivery of novel diag-
nostics has potential to revolutionize the patient care. However, the major challenge 
includes reimbursement system, specifically in obtaining coverage, appropriate 
coding, and value-based payment for diagnostics. To determine the coverage poli-
cies, extent of the tests covered and evidence basis for the coverage decisions by 
U.S. payers for genomic tests in breast cancer. Methods: We reviewed the cover-
age policies for genomic tests in breast cancer, coverage extent, and evidence for 
coverage decisions. An online search of top US insurers was conducted in January 
2014 to identify the coverage policies for genomic tests. In addition to FDA approval, 
the coverage policy and assessments were also reviewed. Results: In this search 
of insurance companies, 22 coverage policies for genomic testing were identified. 
Coverage determinations were made for 5 unique tests for disease diagnosis, prog-
nosis and risk assessment in the 22 policies analyzed. For genomic tests in Breast 
Cancer, one of the 5 tests was approved by the FDA and covered by only one insurer 
that issued a coverage decision on it. Coverage policies specific to disease-related 
genomic tests varied across the insurance companies that were evaluated. The 
Oncotype Dx is covered by all insurers to assess breast cancer recurrence risk, 
but considered investigational. Only 2 diagnostic tests were covered by atleast one 
insurer, however one of the tests was reviewed and covered by all insurers. Humana 
covered two tests; Mammaprint and Oncotype DX. The Mammaprint test for breast 
cancer risk recurrence had discordant coverage policies among tests reviewed by 
more than one insurer. ConClusions: Although some insurers are willing to pro-
vide coverage based on limited evidence of clinical utility, insurance coverage for 
genomic testing is low and variable. This is likely due to few studies published 
that demonstrate clinical utility and availability of alternative screening methods.
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objeCtives: To explore the effects of genetic testing of patients with breast cancer by 
Oncotype DX for decision of further therapy and their prognosis. Methods: Health 
economy model, using Cost-Utility Analysis (CUA), complemented by Budget-Impact 
Analysis (BIA) on public health insurance coverage in Slovakia. Markov Model (life 
time horizon) for BC patient management was developed, comparing diagnosis by 
Oncotype DX and standard diagnostic methods. Outcomes observed were decreased 
by number of women with chemotherapy (CT) and increased by proportion of women 
with hormonal treatment alone (HT) and their Recurence Score (RS, observed from 
test) in horizon of 10 years. Payer perspective and direct health care costs only, asso-
ciated with breast cancer diagnoses patient management were considered in CUA 
and BIA for diagnosis subgroups. Discount rate of 5% was used for costs as well as 
outcomes. Sensitivity analysis for major complications was implemented. Results: 
CUA for Oncotype DX vs. standard care associated with decreased proportion of CT 
and increased proportion of HT with cost per QALY 12 889 € and cost per LY 11 019 € . 
Net costs (BIA) associated with Oncotype DX for cohort of patients 1 200 are 3.92 mil. 
€ . ConClusions: Oncotype DX is considered cost-effective in terms of diagnoses 
and followed treatment of breast cancer patients. Oncologists are able to differentiate 
between a low or intermediate RS and a high RS using standard prognostic criteria. 
Provision of the actual RS changed the treatment recommendations in nearly 40% of 
cases, suggesting that the RS may reduce chemotherapy use.
PCN39
the differeNCes BetWeeN CaNCer drug aPProVaLs iN jaPaN aNd  
the usa
Anderson R1, Brooks-Rooney C2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Singapore Pte Ltd., Singapore
objeCtives: Cancer is amongst the leading causes of death globally and was 
responsible for a total of 8.2 million deaths worldwide in 2012. The aim of this 
study was to investigate the similarities and differences between the approval of 
new molecular entities and biologics for the treatment of cancers in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
